Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genprex Inc (GNPX)

Genprex Inc (GNPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,276
  • Shares Outstanding, K 47,528
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,940 K
  • 60-Month Beta -0.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.05
Trade GNPX with:

Options Overview

Details
  • Implied Volatility 97.27%
  • Historical Volatility 55.35%
  • IV Percentile 17%
  • IV Rank 24.55%
  • IV High 198.35% on 08/20/21
  • IV Low 64.39% on 07/20/21
  • Put/Call Vol Ratio 0.33
  • Today's Volume 68
  • Volume Avg (30-Day) 223
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 2,043
  • Open Int (30-Day) 5,574

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +499,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.58 +3.49%
on 08/20/21
3.30 -19.09%
on 09/02/21
-0.04 (-1.66%)
since 08/17/21
3-Month
2.24 +19.20%
on 08/16/21
3.89 -31.36%
on 06/23/21
-0.82 (-23.50%)
since 06/17/21
52-Week
2.24 +19.20%
on 08/16/21
7.72 -65.41%
on 02/08/21
-1.20 (-31.01%)
since 09/17/20

Most Recent Stories

More News
Genprex to Participate in a Monthly CEO Roadshow Webinar Series

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 2.68 (-1.47%)
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA(TM) Immunogene Therapy in Combination with Tagrisso(R) to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 2.68 (-1.47%)
Genprex Announces Participation in Noble Capital Markets' Virtual Roadshow Series

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it will...

GNPX : 2.68 (-1.47%)
Genprex to Participate in Upcoming May Investor Conferences

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it will...

GNPX : 2.68 (-1.47%)
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer

--Newly licensed technologies include use of Genprex's TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy

GNPX : 2.68 (-1.47%)
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

--Acclaim-1 clinical trial to treat late-stage NSCLC patients whose disease progressed on Tagrisso(R)

GNPX : 2.68 (-1.47%)
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

--Company Expects to Recruit Approximately 15 Sites Across the United States

MRK : 71.41 (-0.78%)
GNPX : 2.68 (-1.47%)
Genprex to Participate in CEO Roadshow Webinar Series

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 2.68 (-1.47%)
Genprex to Receive Inaugural "License of the Year" Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announces today that...

GNPX : 2.68 (-1.47%)
Proactive news headlines including Genprex, INDVR Brands, QC Copper and Gold and Hillcrest EnergyTechnologies

Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

GNPX : 2.68 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 2.87
2nd Resistance Point 2.81
1st Resistance Point 2.77
Last Price 2.68
1st Support Level 2.67
2nd Support Level 2.61
3rd Support Level 2.57

See More

52-Week High 7.72
Fibonacci 61.8% 5.63
Fibonacci 50% 4.98
Fibonacci 38.2% 4.33
Last Price 2.68
52-Week Low 2.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar